Tempest Therapeutics, Inc. — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On November 17, 2026, Tempest Therapeutics received notice of failure to satisfy continued listing standards, triggering Item 3.01 delisting disclosure. No specific listing rule violation, cure period, or remediation plan is detailed in the filing text provided. The company's public market capitalization is approximately $30.1M.
Why this rating
Delisting is business-threatening for a micro-cap biotech; existential risk to public equity, funding, and operations.
Extracted items
Price action (we called it negative)
before filing · preread $0.29 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.